The 3 Things That Matter for AbbVie Now

It's been a challenging past three years for AbbVie (NYSE: ABBV). The pharmaceutical leader lost U.S. patent exclusivity for its top-selling medicine, Humira, and encountered a significant clinical setback that sent its stock price plunging, among other challenges. The drugmaker has lagged the market over this period.Even so, AbbVie might perform very differently through the end of the decade (and beyond), provided it can execute effectively. Here are three key considerations for investors when evaluating an investment in AbbVie.Although AbbVie lost patent exclusivity for Humira, the immunology business remains its largest in terms of revenue. That's because of a duo of immunosuppressants, Skyrizi and Rinvoq, whose sales have been growing rapidly for years.Continue readingWeiter zum vollständigen Artikel bei MotleyFool Weiter zum vollständigen Artikel bei MotleyFool